Rancho Cordova, CA, March 20, 2015 -- SureClinical Inc., an industry-leader in collaborative cloud health sciences applications, announced today a strategic partnership with Triumph Consultancy Services to broaden its eTMF service delivery portfolio. With offices in London, UK, and Raleigh, USA, Triumph is well positioned to provide SureClinical’s growing global customer base with specialized implementation and validation services.
Triumph has been operating for 13 years and has gained significant experience with both Pharma and CRO companies, across small, medium and large organizations. Triumph uses its wealth of clinical knowledge and experience to ensure each project is optimized to the needs of the customer and is delivered efficiently and effectively. Triumph provides both strategic and operational services around technology selection, process reengineering, organizational change management, training delivery, regulatory compliance management, and key performance metric (KPIs) study analysis.
“We are thrilled to partner with Triumph. Their consultative approach to service engagements, ensuring the needs of the customer are put first, as well as their solid track record in clinical system implementation is impressive. Clients can be assured of the very best guidance in both implementing SureClinical eTMF as well as integrating the solution with existing clinical systems.” said Chris Ibell, Chief Strategy Officer and President SureClinical Europe. “Like Triumph, SureClinical is committed to providing a best-in-class cloud eTMF that is immediately accessible to sponsors and their CROs, thereby improving study ROI. Triumph delivers a range of modularized, portfolio services that will ensure a successful implementation of SureClinical eTMF, deployed on a global, FDA and EC-compliant Certified Cloud™."
“We are excited to include the SureClinical Cloud eTMF within our technology services portfolio,” said Duncan Hall, CEO of Triumph. "SureClinical is on the forefront of delivering electronic Trial Master File capture, completion, and digital signing with the latest cloud and mobile technologies. With the majority of clinical regulatory documents still captured on paper, we see a great opportunity to provide SureClinical customers with Triumph’s best practice processes and training accelerators when transitioning their Trial Master File processes to the cloud."
SureClinical eTMF Cloud – Shred the Paper Mountain (TM)
SureClinical’s SureWorkflow and patent-pending high trust digital signing is part of an integrated solution, enabling clinical trial sponsors, CRO’s, investigators and stakeholders to collaborate, complete and Esign documents through automated workflows, eliminating paper at its origin. CRO’s, sponsors, and investigators can readily and securely sign documents from any connected mobile device, anywhere in the world without opening ports in firewalls or requiring federation of security. Moreover, since it is Cloud, SureClinical customers can activate studies within minutes delivering scale-up and scale-down flexibility based on need, without having to invest in underused on premise infrastructure or software. SureClinical eTMF Cloud automates and streamlines clinical processes, eliminates paper, which is good for the customer, environment, industry, and the customer’s bottom-line.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.